The proposed reform aims to achieve savings of €20 billion in 2024 and over €40 billion by 2030, with a cabinet vote expected soon. While Warken emphasizes stabilizing contribution rates, SPD Secretary Klüssendorf criticizes the plan for shifting burdens onto insured individuals, advocating for increased pharmaceutical company contributions instead. The Greens are reportedly drafting a counterproposal focused on lowering contributions.